<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037647</url>
  </required_header>
  <id_info>
    <org_study_id>20070028</org_study_id>
    <nct_id>NCT01037647</nct_id>
  </id_info>
  <brief_title>VLDL-triglyceride Kinetics in Type 2 Diabetes</brief_title>
  <official_title>VLDL-triglyceride Kinetics and -Metabolism in the Post Absorptive State and During Hyperinsulinemia in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Novo Nordic Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is associated with diabetic dyslipidemia, which is a major risk factor for
      coronary heart disease. Triglycerides (TG) and cholesterol are transported in the system of
      lipoproteins, and the metabolism of these lipids in plasma is closely interrelated. Evidence
      suggests that increased concentration of very low-density lipoprotein triglyceride (VLDL-TG)
      is a central pathophysiological feature of the lipid and lipoprotein abnormalities in
      diabetic dyslipidemia.

      The objective of this study was to investigate VLDL-TG kinetics and aspects of peripheral
      VLDL-TG metabolism, i.e. to what extent VLDL-TG associated fatty acids (FA) are oxidized or
      deposited in regional adipose tissue, in subjects with type 2 diabetes and healthy controls
      in the postabsorptive state and during acute hyperinsulinemia using ex-vivo labeled VLDL-TG
      tracers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VLDL-TG production and clearance rates</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>VLDL-TG oxidation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-TG subcutaneous adipose tissue storage</measure>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">22</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetic men</arm_group_label>
    <description>Men with type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy men</arm_group_label>
    <description>Healthy men</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperinsulinemic euglycemic glucose clamp</intervention_name>
    <description>Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).</description>
    <arm_group_label>Type 2 diabetic men</arm_group_label>
    <arm_group_label>Healthy men</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples Subcutaneous adipose tissue biopsies Muscle biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        11 men with type diabetes and 11 healthy men, matched for age and BMI.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:

          -  Known disease except type 2 diabetes (type 2 diabetic subjects)

          -  Smoking

          -  Alcohol abuse

          -  Prescription medication expect oral antidiabetics (type 2 diabetic subjects)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Søren Nielsen, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical department M (Endocrinology and Diabetes), Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>DK</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>November 4, 2011</last_update_submitted>
  <last_update_submitted_qc>November 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Diabetic dyslipidemia</keyword>
  <keyword>VLDL-TG kinetics</keyword>
  <keyword>VLDL-TG metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

